Kenji Tamura

Summary

Affiliation: Kinki University
Country: Japan

Publications

  1. ncbi request reprint Gefitinib in non-small cell lung cancer
    Kenji Tamura
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Expert Opin Pharmacother 6:985-93. 2005
  2. ncbi request reprint Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses
    Kenji Tamura
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Cancer Chemother Pharmacol 60:285-93. 2007
  3. doi request reprint Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 7:599-606. 2008
  4. doi request reprint A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904)
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka 589 8511, Japan
    Jpn J Clin Oncol 40:992-4. 2010
  5. doi request reprint Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors
    Toshio Shimizu
    Department of Medical Oncology, Kinki University School of Medicine, Ohno Higashi, Osaka Sayama, Japan
    Cancer Chemother Pharmacol 65:243-50. 2010
  6. ncbi request reprint Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer
    Tomohiro Ozaki
    Department of Medical Oncology, Kinki University School of Medicine, Nara Hospital, Otoda, Ikoma, Nara, Japan
    Anticancer Res 27:2657-65. 2007
  7. ncbi request reprint Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells
    Masato Ikeda
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Cancer Lett 248:292-8. 2007
  8. ncbi request reprint Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Cancer Res 67:2046-53. 2007
  9. ncbi request reprint Amrubicin for non-small-cell lung cancer and small-cell lung cancer
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Invest New Drugs 25:499-504. 2007
  10. doi request reprint Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study
    Isamu Okamoto
    Kinki University Faculty of Medicine, Osaka City General Hospital, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    J Clin Oncol 28:5240-6. 2010

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Gefitinib in non-small cell lung cancer
    Kenji Tamura
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Expert Opin Pharmacother 6:985-93. 2005
    ..Appropriate patient selection by clinical characteristics or genetical information is needed, both for future clinical trials of gefitinib and its routine use in the clinic among patients with advanced NSCLC...
  2. ncbi request reprint Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses
    Kenji Tamura
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Cancer Chemother Pharmacol 60:285-93. 2007
    ....
  3. doi request reprint Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 7:599-606. 2008
    ....
  4. doi request reprint A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904)
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka 589 8511, Japan
    Jpn J Clin Oncol 40:992-4. 2010
    ..We could not determine the recommended dose of this combination because of intolerable toxicities and no efficacy. Therefore, it is difficult to forward this combination chemotherapy toward further studies...
  5. doi request reprint Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors
    Toshio Shimizu
    Department of Medical Oncology, Kinki University School of Medicine, Ohno Higashi, Osaka Sayama, Japan
    Cancer Chemother Pharmacol 65:243-50. 2010
    ..We have performed a phase I study to determine the safety profile, pharmacokinetics, and antitumor activity of D-19575 in Japanese patients with advanced solid tumors..
  6. ncbi request reprint Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer
    Tomohiro Ozaki
    Department of Medical Oncology, Kinki University School of Medicine, Nara Hospital, Otoda, Ikoma, Nara, Japan
    Anticancer Res 27:2657-65. 2007
    ..The primary objective of this study was to determine the maximum tolerated dose (MTD), the toxicity profile and the recommended dose (RD) for phase II of a combination of S-1 and weekly administration of docetaxel...
  7. ncbi request reprint Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells
    Masato Ikeda
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Cancer Lett 248:292-8. 2007
    ..Furthermore, depletion of survivin resulted in G(2)-M arrest, suggesting that down-regulation of survivin by p53 contributes to the p53-dependent G(2)-M checkpoint triggered by DNA damage...
  8. ncbi request reprint Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Cancer Res 67:2046-53. 2007
    ..These results reveal distinct biochemical properties of endogenous mutant forms of EGFR expressed in NSCLC cell lines and may have implications for treatment of this condition...
  9. ncbi request reprint Amrubicin for non-small-cell lung cancer and small-cell lung cancer
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Invest New Drugs 25:499-504. 2007
    ..6 and 10.3 months, and 1-year survival rate was 46 and 40%, respectively. These results are promising for the treatment of both NSCLC and SCLC. Further clinical trials will clarify the status of amrubicin in the treatment of lung cancer...
  10. doi request reprint Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study
    Isamu Okamoto
    Kinki University Faculty of Medicine, Osaka City General Hospital, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    J Clin Oncol 28:5240-6. 2010
    ....
  11. ncbi request reprint A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients
    Hiroyasu Kaneda
    Department of Medical Oncology, Kinki University School of Medicine, Osaka 589 8511, Japan
    Anticancer Res 26:2479-85. 2006
    ....
  12. ncbi request reprint Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer
    Hiroyasu Kaneda
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 46:247-54. 2004
    ..We have retrospectively reviewed data of all patients who received a single regimen of gefitinib in our institution from August 1998 until July 2003...
  13. ncbi request reprint Pemetrexed-induced edema of the eyelid
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 54:241-2. 2006
    ..We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known...
  14. ncbi request reprint Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin
    Kimio Yonesaka
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Int J Cancer 118:812-20. 2006
    ..siRNA targeting of survivin could be potentially useful for increasing sensitivity to anticancer drugs, especially in drug-resistant cells with mutated p53...
  15. ncbi request reprint Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience
    Toshio Shimizu
    Department of Medical Oncology, Kinki University Nara Hospital, 1248 1 Otoda cho, Ikoma, Nara, 630 0293, Japan
    Int J Clin Oncol 12:218-23. 2007
    ..The oxaliplatin/fluorouracil/leucovorin (FOL-FOX regimen) is an effective and generally well-tolerated regimen in Western clinical studies of advanced colorectal cancer. In Japan, oxaliplatin was approved in April 2005...
  16. ncbi request reprint Skeletal metastases in non-small cell lung cancer: a retrospective study
    Asuka Tsuya
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama City, Osaka 589 8511, Japan
    Lung Cancer 57:229-32. 2007
    ..Therefore, we planned a retrospective study to investigate the clinical impact of SREs, and to compare differences in the therapeutic outcome between patients with and without skeletal metastases or SRE...
  17. ncbi request reprint Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    J Thorac Oncol 1:684-91. 2006
    ....
  18. ncbi request reprint Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells
    Takefumi Komiya
    Division of Medical Oncology, Kinki University School of Medicine, 377 2 Ohnohigashi, 589 8511, Osakasayama City, Osaka, Japan
    Cancer Chemother Pharmacol 51:202-8. 2003
    ..The objective of this study was to determine the cytotoxicity of ritterazine B to non-small-cell lung cancer (NSCLC) cells in vitro and its effects on the cell cycle and apoptosis...
  19. ncbi request reprint Molecular target-based cancer therapy: tyrosine kinase inhibitors
    Kenji Tamura
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Int J Clin Oncol 8:207-11. 2003
    ..Early data show that they are generally well tolerated and have provided evidence of against activity tumors. HER-TK inhibitors are likely to have a substantial impact on the treatment of cancer patients...
  20. doi request reprint Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS
    Kazuko Matsumoto
    Department of Genome Biology, Kinki University School of Medicine, Osaka, Japan
    J Proteome Res 8:457-62. 2009
    ..Our results suggest that glycosylation analysis may provide useful information for determining clinical cancer therapy and provide novel insight into biomarker studies using glycobiological tools in the field of breast cancer...
  21. ncbi request reprint [Targeted therapies for lung cancer]
    Kenji Tamura
    Rinsho Ketsueki 49:616-21. 2008
  22. ncbi request reprint Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancer
    Gyo Asai
    Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
    J Thorac Oncol 1:226-30. 2006
    ..This combination therapy must be planned only after careful consideration of the drug-drug interaction...
  23. ncbi request reprint Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902
    Hiroshi Saito
    Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Okazaki Aichi, Japan
    J Clin Oncol 24:5247-52. 2006
    ..We amended the protocol to evaluate IP after EP with concurrent twice-daily TRT in a single-arm phase II study because of an unacceptable toxicity in IPE...
  24. ncbi request reprint Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
    Masahiko Ando
    Department of Preventive Services, Kyoto University School of Public Health, Kyoto, Japan
    J Clin Oncol 24:2549-56. 2006
    ..We examined the prevalence of and risk factors for gefitinib-induced ILD associated with practical use of the drug in Japanese with non-small-cell lung cancer (NSCLC)...
  25. doi request reprint Therapy-related acute promyelocytic leukemia caused by hormonal therapy and radiation in a patient with recurrent breast cancer
    Makiko Ono
    Breast and Medical Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 38:567-70. 2008
    ..This patient is thought to be a rare case of secondary leukemia, since the leukemia might have been caused by hormonal therapy and regional radiation without chemotherapy...
  26. ncbi request reprint Effects of airborne particulate matter on respiratory morbidity in asthmatic children
    Lu Ma
    Department of Public Health, Hyogo College of Medicine, Japan
    J Epidemiol 18:97-110. 2008
    ..The effects of airborne particulate matter (PM) are a major human health concern. In this panel study, we evaluated the acute effects of exposure to PM on peak expiratory flow (PEF) and wheezing in children...
  27. ncbi request reprint [Effects of quantity of Japanese cedar pollen, air pollution and urbanization on allergic rhinitis morbidity in Ibaraki prefecture]
    Wu Chunling
    Endo Otolaryngologic Clinic
    Nihon Koshu Eisei Zasshi 49:631-42. 2002
    ..The purpose of the present investigation was to clarify the Japanese cedar pollinosis contribution to morbidity, and also clarifying the influence of air pollution and medical resources on the crisis and symptoms of allergic rhinitis...